Ask a doctor about a prescription for Enyglid 0.5 mg tablets
Patient Information Leaflet
Enyglid 0.5 mg EFG tablets
Enyglid 1 mg EFG tablets
Enyglid 2 mg EFG tablets
repaglinide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Enyglid is an oral antidiabetic medicine that contains repaglinide, which helps your pancreas produce more insulin and lowers your blood sugar (glucose) level.
Type 2 diabetes is a disease in which your pancreas does not produce enough insulin to control your blood sugar level or in which your body is not able to use the insulin it produces properly.
Enyglid is used to control type 2 diabetes in adults, in addition to diet and exercise: treatment should be started if diet, exercise, and weight reduction alone have not been able to control (or lower) your blood sugar level.
Enyglid can also be given with metformin.
It has been shown that Enyglid lowers your blood sugar level, which helps to prevent complications from diabetes.
Do not take Enyglid
Warnings and precautions
Consult your doctor before taking Enyglid:
Consult your doctorif any of the above applies to you. Enyglid may not be suitable for you. Your doctor will advise you.
Children and adolescents
Do not take this medicine if you are under 18 years old.
If you have low blood sugar (hypoglycaemia)
You may have hypoglycaemia if your blood sugar level is too low. This can happen:
Warning signs of hypoglycaemiaappear suddenly and can be: cold sweat, cool pale skin, headache, fast heartbeat, nausea, excessive hunger, temporary visual disturbances, fatigue, unusual weakness, nervousness or tremor, anxiety, confusion, and difficulty concentrating.
If your blood sugar level is low or if you feel that you are going to have hypoglycaemia:take glucose tablets or a sugary product or drink, and then rest.
When the symptoms of hypoglycaemia have disappeared or when your blood sugar levels have stabilised, continue with your treatment with Enyglid.
Tell others that you have diabetesand if you lose consciousnessdue to hypoglycaemia, they should lay you on your side and seek immediate medical assistance. They should not give you anything to eat or drink, as you may choke.
If your blood sugar level is very high
Your blood sugar level may be very high (hyperglycaemia). This can happen:
Warning signs of high blood sugarappear gradually. These include: excessive urination, thirst, dry skin, and a dry mouth feeling. Inform your doctor. You may need to adjust the dose of Enyglid, your diet, or exercise.
Using Enyglid with other medicines
Tell your doctoror pharmacist if you are taking, have recently taken, or might take any other medicines.
If your doctor prescribes it, you can take Enyglid with metformin, another diabetes medicine.
If you are taking gemfibrozil (used to lower fat levels in the blood), you should not take Enyglid.
Your body's response to Enyglid may change if you take other medicines, especially:
Using Enyglid with alcohol
Alcohol may change the effect of Enyglid on lowering your blood sugar level. Be aware of the signs of hypoglycaemia.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Do not take Enyglid if you are pregnant or planning to become pregnant.
Do not take Enyglid if you are breast-feeding.
Driving and using machines
Your ability to drive or use machines may be affected if your blood sugar level is too low or too high. Be aware that you may put yourself or others at risk.
Consult your doctor about the possibility of driving a car if:
Enyglid contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor again.
Your doctor will calculate your dose.
Do not take more Enyglid than your doctor has recommended.
If you take more Enyglid than you should
If you take too many tablets, your blood sugar level may become too low and cause hypoglycaemia. Please read what hypoglycaemia is and how to treat it in the section If you have low blood sugar (hypoglycaemia).
If you forget to take Enyglid
If you miss a dose, take the next dose as you normally would.
Do not take a double dose to make up for forgotten doses.
If you stop taking Enyglid
Be aware that the desired effect will not be achieved if you stop taking Enyglid. Your diabetes may worsen. If any change in your treatment is needed, consult your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Hypoglycaemia
The most common side effect is hypoglycaemia, which can affect up to 1 in 10 people (see If you have low blood sugar (hypoglycaemia) in section 2). Hypoglycaemic reactions are usually mild or moderate but can occasionally lead to loss of consciousness or hypoglycaemic coma. If this happens, you need immediate medical assistance.
Allergic reactions
Cases of allergic reactions are very rare (may affect up to 1 in 10,000 people). Symptoms like swelling, difficulty breathing, fast heartbeat, dizziness, and sweating may be signs of an anaphylactic reaction. Contact your doctor immediately.
Other side effects
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 1,000 people)
Rare(may affect up to 1 in 10,000 people):
Frequency not known(cannot be estimated from the available data)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children
Do not use this medicine after the expiry date which is stated on the blister or carton after EXP. The expiry date refers to the last day of that month.
Store in the original package to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Enyglid contains
Appearance of Enyglid and pack contents
The 0.5 mg tablets are white, round, and biconvex with bevelled edges.
The 1 mg tablets are pale yellow-brown, round, and biconvex with bevelled edges and possible dark spots.
The 2 mg tablets are pink, mottled, round, and biconvex with bevelled edges and possible dark spots.
Available in packs of 30, 60, 90, 120, 180, 270, or 360 tablets in blisters. Not all pack sizes may be marketed.
Marketing authorisation holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
ManufacturerKRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
For further information about this medicine, please contact the local representative of the marketing authorisation holder:
Belgium KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 | Lithuania UAB KRKA Lietuva Tel: + 370 5 236 27 40 |
Luxembourg KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) | |
Czech Republic KRKA CR, s.r.o. Tel: + 420 (0) 221 115 150 | Hungary KRKA Magyarország Kereskedelmi Kft. Tel.: + 36 (1) 355 8490 |
Denmark KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) | Malta
Tel: + 356 21 445 885 |
Germany TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 | Netherlands KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) |
Estonia KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 658 | Norway KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Greece KRKA ΕΛΛΑΣ ΕΠΕ Τηλ: +30 2100101613 | Austria KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 300 |
Spain KRKA Farmacéutica, S.L. Tel: + 34 911 61 03 80 | Poland KRKA-POLSKA Sp. z o.o. Tel.: + 48 (0)22 573 7500 |
France KRKA France Eurl Tel: + 33 (0)1 57 40 82 25 | Portugal KRKA Farmacêutica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 650 |
Croatia KRKA – FARMA d.o.o Tel: + 385 1 6312 100 | Romania KRKA Romania S.R.L., Bucharest Tel: + 4021 310 66 05 |
Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3710 | Slovenia KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 100 |
Iceland LYFIS ehf. Tel: + 354 534 3500 | Slovakia KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 501 |
Italy KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8841 | Finland KRKA Finland Oy Tel: + 358 20 754 5330 |
Cyprus KI.PA. (PHARMACAL) LIMITED Τηλ: + 357 24 651 882 | Sweden KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Latvia KRKA Latvija SIA Tel: + 371 6 733 86 10 | United Kingdom (Northern Ireland) KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3710 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency (EMA) website http://www.ema.europa.eu/.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Enyglid 0.5 mg tablets – subject to medical assessment and local rules.